Journal of Global Pharma Technology
Vol.11, Issue6, P. 180-191
Аннотация:
The World Health Organization (WHO) estimates that in 2015 cancer was the first or second leading death cause before the age of 70 in 91 out of 172 countries, and ranked third or fourth in the other 22. This study analyzes three main types of targeted cancer therapies: low molecular weight inhibitors; monoclonal antibodies; and immunotoxins. The low molecular weight inhibitors analyzed in the paper are Gleevec, Sprycel, VEGF targeting, Nexavar, Tykerb, Iressa, EGFR and HER2 Targeting, Torisel. The monoclonal antibodies include VEGF, EGFR and HER2, Herceptin, Avastin, CD20, Rituxan, Zevalin, Campath. The DAB389IL-2 (or Ontak - FDA Approved Medication for the Treatment of Acute T Cell Lymphoma) represents immunotoxins. It proves that depending on the location of the unregulated protein, different approaches are implemented. Monoclonal antibodies can block interactions and functions of unregulated proteins within the extracellular compartment, while low molecular weight inhibitors can rea
Ключевые слова:
Gleevec; Low molecular weight inhibitors; Monoclonal antibodies; Pro-angiogenic molecules
alemtuzumab; antineoplastic agent; atezolizumab; BCR ABL protein; bevacizumab; CD20 antigen; CD52 antigen; dasatinib; denileukin diftitox; epidermal growth factor receptor; gefitinib; ibritumomab tiuxetan; imatinib; immunotoxin; lapatinib; mammalian target of rapamycin; monoclonal antibody; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; rituximab; sorafenib; temsirolimus; trastuzumab; vasculotropin; vasculotropin antibody; Article; cancer growth; carcinogenesis; cell growth; cell proliferation; human; ligand binding; malignant neoplasm; molecularly targeted therapy; protein targeting; spermatogenesis
Tikhonova Yu. A. Yuliya Anatolyevna 1972-
Qiu S.
Тихонова Ю. А. Юлия Анатольевна 1972-
Qиу С.
Targeted systems in cancer treatment
Текст визуальный непосредственный
Journal of Global Pharma Technology
Vol.11, Issue6 P. 180-191
2019
Статья
Gleevec Low molecular weight inhibitors Monoclonal antibodies Pro-angiogenic molecules
alemtuzumab antineoplastic agent atezolizumab BCR ABL protein bevacizumab CD20 antigen CD52 antigen dasatinib denileukin diftitox epidermal growth factor receptor gefitinib ibritumomab tiuxetan imatinib immunotoxin lapatinib mammalian target of rapamycin monoclonal antibody phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase rituximab sorafenib temsirolimus trastuzumab vasculotropin vasculotropin antibody Article cancer growth carcinogenesis cell growth cell proliferation human ligand binding malignant neoplasm molecularly targeted therapy protein targeting spermatogenesis
The World Health Organization (WHO) estimates that in 2015 cancer was the first or second leading death cause before the age of 70 in 91 out of 172 countries, and ranked third or fourth in the other 22. This study analyzes three main types of targeted cancer therapies: low molecular weight inhibitors; monoclonal antibodies; and immunotoxins. The low molecular weight inhibitors analyzed in the paper are Gleevec, Sprycel, VEGF targeting, Nexavar, Tykerb, Iressa, EGFR and HER2 Targeting, Torisel. The monoclonal antibodies include VEGF, EGFR and HER2, Herceptin, Avastin, CD20, Rituxan, Zevalin, Campath. The DAB389IL-2 (or Ontak - FDA Approved Medication for the Treatment of Acute T Cell Lymphoma) represents immunotoxins. It proves that depending on the location of the unregulated protein, different approaches are implemented. Monoclonal antibodies can block interactions and functions of unregulated proteins within the extracellular compartment, while low molecular weight inhibitors can rea